SCHEMBL30178446

SCHEMBL30178446

Cc1cc(-n2nc3c(c2-n2cc[nH]c2=O)CN(C(=O)OC(C)(C)C)CC3)ccc1F

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ C5AR1 P21730 7/20 0.42
▸ F12 P00748 2/20 0.40
▸ HPGDS O60760 2/20 0.37
▸ DPP4 P27487 1/20 0.36
▸ DPP8 Q6V1X1 1/20 0.36
▸ DPP9 Q86TI2 1/20 0.36
▸ DPP7 Q9UHL4 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ TP53 P04637 1/20 0.35
▸ ESR2 Q92731 1/20 0.35
▸ PARP1 P09874 1/20 0.35
▸ TNKS2 Q9H2K2 1/20 0.35
▸ PARP2 Q9UGN5 1/20 0.35
▸ MAP3K14 Q99558 1/20 0.35
▸ NR1H2 P55055 1/20 0.35
▸ TGM2 P21980 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20015372 1.00 C5AR1 (0.42) C5AR1F12HPGDSDPP4DPP8
SCHEMBL31692488 0.96 C5AR1 (0.39) C5AR1F12HPGDSTHRBTP53
SCHEMBL21183596 0.92 C5AR1 (0.41) C5AR1F12HPGDSTHRBESR2
SCHEMBL20014993 0.88 C5AR1 (0.41) C5AR1F12HPGDSTP53ESR2
SCHEMBL21175380 0.88 DPP4 (0.39) DPP4DPP8DPP9DPP7
SCHEMBL31692183 0.87 C5AR1 (0.38) C5AR1F12HPGDSTHRBTP53
SCHEMBL20015363 0.87 C5AR1 (0.41) C5AR1F12HPGDSTHRBESR2
SCHEMBL22750895 0.83 C5AR1 (0.32) C5AR1DPP4DPP8DPP9DPP7
SCHEMBL20015371 0.82 F12 (0.50) C5AR1F12HPGDSDPP4DPP8
SCHEMBL29475107 0.82 F12 (0.50) C5AR1F12HPGDSDPP4DPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260103463-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2026-04-16 — — US disclosed
US-20260055105-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2026-02-26 — — US disclosed
US-12410168-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-09-09 — — US disclosed
US-12331050-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-06-17 — — US disclosed
US-12331049-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-06-17 — — US disclosed
US-RE50455-E1 Pyrazolopyridine derivative having GLP-1 receptor agonist effect CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-06-10 — — US disclosed
US-20250092041-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-03-20 — — US disclosed
US-12187724-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-01-07 — — US disclosed
US-20250002494-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-01-02 — — US disclosed
US-20240262824-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-08-08 — — US disclosed
US-20240246971-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-07-25 — — US disclosed
EP-3517538-B1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI PHARMACEUTICAL CO LTD (JP) 2024-03-13 — — EP disclosed
US-20230382912-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-11-30 — — US disclosed
US-11814381-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-11-14 — — US disclosed
EP-4134367-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-02-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12410168-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect GLP1R, GPR119, GIPR C5AR1 3777/4885F12 2777/4885HPGDS 3039/4885
US-20230382912-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT GLP1R, GPR119, GIPR C5AR1 3777/4885F12 2777/4885HPGDS 3039/4885
US-12331049-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect GLP1R, GPR119, GIPR C5AR1 3777/4885F12 2777/4885HPGDS 3039/4885
US-20260103463-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT GLP1R, GPR119, GIPR C5AR1 1872/4885F12 2828/4885HPGDS 3489/4885
US-12187724-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect GLP1R, GPR119, GIPR C5AR1 3777/4885F12 2777/4885HPGDS 3039/4885
US-20240246971-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT GLP1R, GPR119, GIPR C5AR1 3777/4885F12 2777/4885HPGDS 3039/4885
US-20250002494-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT GLP1R, GPR119, GIPR C5AR1 3777/4885F12 2777/4885HPGDS 3039/4885
US-11814381-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect GLP1R, GPR119, GIPR C5AR1 3728/4885F12 4300/4885HPGDS 3269/4885
US-20240262824-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT GLP1R, GPR119, GIPR C5AR1 3777/4885F12 2777/4885HPGDS 3039/4885
US-20260055105-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT GLP1R, GIPR, GPR119 C5AR1 3680/4885F12 3538/4885HPGDS 3479/4885
US-12331050-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect GLP1R, GPR119, GIPR C5AR1 3777/4885F12 2777/4885HPGDS 3039/4885
US-20250092041-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT GLP1R, GPR119, GIPR C5AR1 3728/4885F12 4300/4885HPGDS 3269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback